这一点在西罗莫司标签的黑框警告中有提示。
This information is in the Boxed Warning of the sirolimus label.
FDA正在酝酿是否需要修改西罗莫司的标签信息。
The FDA is determining whether a labeling change for sirolimus is needed.
治疗药物监测不应作为调整西罗莫司治疗的唯一根据。
Therapeutic drug monitoring should not be the sole basis for adjusting sirolimus therapy.
不能口服片剂的患者应给予西罗莫司口服液，并指导给药。
Patients unable to take the tablets should be prescribed the sirolimus oral solution and instructed in its use.
蛋白尿症与肾小球的病变以及西罗莫司(免疫抑制剂)的使用相关。
Proteinuria was associated with the presence of graft glomerular pathology and the use of sirolimus.
西罗莫司用于在13岁及以上接受肾移植患者中预防器官排斥反应。
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving kidney transplants.
在西罗莫司组中因不良事件而导致停药的也多于继续使用CNI治疗的患者。
Drug discontinuation due to an adverse event was also more frequent in the sirolimus cohort compared to those patients continued on CNI.
这项先导试验是设计用来评估西罗莫司用于肾功不全肝移植受体的安全性和有效性的。
This pilot trial was designed to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction.
再次血运重建率在西罗莫司和紫杉醇的两个临床试验类似，分别为5.6%和5.3%。
Revascularization rates were similar with the sirolimus - and paclitaxel-eluting stents in the two trials, at 5.6% versus 5.3%, respectively.
Kushwaha和他的同事试验西罗莫司作为可选择的抗增值免疫抑制药物的使用。
Kushwaha and colleagues tested the use of sirolimus as an alternative anti-proliferative immunosuppressant drug.
所有的患西罗莫司诱发性肺炎的病人资料均进行了记录，我们回顾性分析了这些病人的资料数据。
All cases of sirolimus-induced pneumonitis were recorded and a retrospective review of the case notes of such patients was undertaken for the purpose of this analysis.
腹水作为一种不良反应其发生率为3%至20%，但是先前并没有认为西罗莫司和乳糜性腹水相关。
Ascites is an adverse effect with an incidence between 3% and 20%, but no relation between sirolimus and chylous ascites was previously established.
这种药物是瑞帕霉素，又被称为西罗莫司，目前被用于作为一种免疫抑制剂，有助于防止新移植肾脏发生排异。
The drug is rapamycin, also called sirolimus, and is currently used as an immunosuppressant, to help prevent rejection of a new, transplanted kidney.
这些数据表明，基于新型西罗莫司的免疫抑制和移植后满意的结果相关，甚至在选择的患者超越米兰标准之外时。
These data suggest that de noo sirolimus-based immunosuppression is associated with satisfactory outcomes after transplantation, een in selected patients beyond Milan criteria.
总共804名成功植入西罗莫司或紫杉醇药物洗脱支架的病人，检查了他们在服用了600mg负荷计量的氯吡格雷之后的治疗后血小板活性。
A total of 804 patients who had successful sirolimus- or paclitaxel-eluting stent implantation were assessed for post-treatment platelet reactivity after a loading dose of 600 mg of clopidogrel.
总共804名成功植入西罗莫司或紫杉醇药物洗脱支架的病人，检查了他们在服用了600mg负荷计量的氯吡格雷之后的治疗后血小板活性。
A total of 804 patients who had successful sirolimus- or paclitaxel-eluting stent implantation were assessed for post-treatment platelet reactivity after a loading dose of 600 mg of clopidogrel.
应用推荐